Cargando…
Cap dependent translation contributes to resistance of myeloma cells to bortezomib
Multiple myeloma (MM) is the second most predominant blood malignancy. Proteasome inhibitors like bortezomib have increased life expectancy, but eventually patients develop resistance to therapy. It was proposed that bortezomib acts through the induction of the Unfolded Protein Response (UPR), i.e.,...
Autores principales: | Mancino, Marilena, Grosso, Stefano, Terragna, Carolina, Borsi, Enrica, Cavo, Michele, Biffo, Stefano |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718057/ https://www.ncbi.nlm.nih.gov/pubmed/26824026 http://dx.doi.org/10.4161/trla.27245 |
Ejemplares similares
-
Role of microRNAs in translation regulation and cancer
por: Oliveto, Stefania, et al.
Publicado: (2017) -
The genetic and genomic background of multiple myeloma patients achieving complete response after induction therapy with bortezomib, thalidomide and dexamethasone (VTD)
por: Terragna, Carolina, et al.
Publicado: (2015) -
Hypoxia inducible factor-1 alpha as a therapeutic target in multiple myeloma
por: Borsi, Enrica, et al.
Publicado: (2014) -
Drug resistance in multiple myeloma: Soldiers and weapons in the bone marrow niche
por: Solimando, Antonio Giovanni, et al.
Publicado: (2022) -
Sensitivity of Global Translation to mTOR Inhibition in REN Cells Depends on the Equilibrium between eIF4E and 4E-BP1
por: Grosso, Stefano, et al.
Publicado: (2011)